Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
US FDA approves BridgeBio's drug for rare heart condition
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
Medscape1mon
Cardiac Amyloidosis: An Approach to Diagnosis and Management
Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Cardiac amyloidosis has a wide spectrum of clinical manifestations but the ...
STAT21h
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
New Hampshire Union Leader15d
Mayo Clinic Q and A: What is cardiac amyloidosis?
My dad was diagnosed with cardiac amyloidosis shortly after his 70th birthday. It’s difficult to pronounce let alone understand. What is cardiac amyloidosis? Am I at risk ...